The invention belongs to the field of biomarkers, and particularly relates to screening and application of a biomarker related to an AD cell model constructed by A beta induction. The biomarker comprises one or a combination of more of the following components: Cysteine Desulfurase, mistoral, the code is NFS1, NADH (Nicotinamide Adenine Dinucleotide) dehydrogenase [ubiquitin] 1 alpha subcomplex subunit 9, mitochondrial, the code is NDUFA 9; 3-hydroxyacyl-CoA dehydrogenase type-2, and the code is HSD17B10; Cytochrome c oxidase subunit NDUFA4, and the code is NDUFA4; NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial, the code is NDUFS1; Succinate dehydrogenase[ubiquinone]iron-sulfur subunit, mitochondrial, the code is SDHB; NADH dehydrogenase[ubiquinone]iron-sulfur protein 4, mitochondrial, the code is NDUFS4; Lipoprotein lipase, the code is LPL; NADH dehydrogenase[ubiquinone]1 alpha subcomplex subunit 5, the code is NDUFA5. A proteomics method is adopted, a group of biomarkers are found in an A beta-induced AD cell model, and the biomarkers are found to be mutually matched in the A beta-induced AD cell model and jointly play an important role. The method for detecting the AD cell model constructed through A beta induction is enriched, and a new target is provided for clinical research.